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Emerging evidence suggests that diabetes affects cognitive function and increases the
incidence of dementia. However, the mechanisms by which diabetes modifies cognitive
function still remains unclear. Morphologically, diabetes is associated with neuronal loss in
the frontal and temporal lobes including the hippocampus, and aberrant functional connec-
tivity of the posterior cingulate cortex and medial frontal/temporal gyrus. Clinically, diabetic
patients show decreased executive function, information processing, planning, visuospa-
tial construction, and visual memory. Therefore, in comparison with the characteristics of
AD brain structure and cognition, diabetes seems to affect cognitive function through not
only simple AD pathological feature-dependent mechanisms but also independent mech-
anisms. As an Aβ/tau-independent mechanism, diabetes compromises cerebrovascular
function, increases subcortical infarction, and might alter the blood–brain barrier. Dia-
betes also affects glucose metabolism, insulin signaling, and mitochondrial function in
the brain. Diabetes also modifies metabolism of Aβ and tau and causes Aβ/tau-dependent
pathological changes. Moreover, there is evidence that suggests an interaction between
Aβ/tau-dependent and independent mechanisms. Therefore, diabetes modifies cognitive
function through Aβ/tau-dependent and independent mechanisms. Interaction between
these two mechanisms forms a vicious cycle.
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INTRODUCTION
More than 30 million patients suffer from dementia (1), while
285 million battle diabetes in this aging society (2). Emerging evi-
dence suggests that diabetes increases the incidence of dementia
(3–8). Indeed, diabetes in mid-life is associated with mild cog-
nitive impairment (MCI) (3), and impaired glycemia increases
disease progression to dementia in patients with MCI (4). More-
over, numerous epidemiological studies have also demonstrated
that patients with diabetes have a significantly higher risk of
developing AD (5–8). While genetic and non-genetic risk factors
contribute to sporadic AD (9),APOEε4 is the strongest genetic risk
factor for sporadic AD and is believed to promote the development
of senile plaques. However, the mechanisms by which diabetes
modifies cognitive function still remain unclear (10). Here, we
review recent advances in brain alterations and clinical symptoms
in dementia associated with diabetes and its Aβ/tau-dependent
and independent mechanisms.
BRAIN ALTERATIONS IN DEMENTIA ASSOCIATED WITH
DIABETES
Diabetes causes functional and structural deficits in the brain
(Table 1). Diabetes is associated with reduced volume of the
Abbreviations: AMPK, AMP-activated protein kinase; APP, amyloid precursor pro-
tein; BBB, blood–brain barrier; IGF-1, insulin-like growth factor-1; IRS-2, insulin
receptor substrate-2; MCI, mild cognitive impairment; RAGE, receptor for advanced
glycation endproducts.
hippocampus (3, 11), whole brain (3), gray (12), and white
matter (11). Gray matter loss is distributed in the medial
temporal, anterior cingulate, and medial frontal lobes (3, 11,
12), and white matter loss occurs in the frontal and tempo-
ral regions (11), whereas, in AD, gray matter loss is in tempo-
ral lobe, hippocampus, entorhinal, and parietal lobes (13–15),
and white matter loss is in the temporal region (16). In addi-
tion to neuronal loss, diabetes also affects functional connec-
tivity. Resting-state functional connectivity, measured by func-
tional MRI, is used to access brain function. Disruption of
resting-state functional connectivity in the default mode net-
work, which is most active during rest, is recently believed
to be a predictor of current and future cognitive dysfunc-
tion, especially in AD (17, 18). Diabetic patients develop aber-
rant functional connectivity of the posterior cingulate cortex
with the medial temporal gyrus (19) and medial frontal gyrus
(20), reflecting white matter abnormalities in diabetes. Dia-
betic patients also have decreased spontaneous brain activity in
the occipital lobe and postcentral gyrus (21). Moreover, func-
tional MRI during task performance demonstrates that diabetic
patients show reduced activation of the dorsolateral prefrontal
cortex during encoding (22). These studies suggest that dia-
betes is associated with neuronal loss in the frontal and tem-
poral lobes including the hippocampus, and aberrant functional
connectivity between the posterior cingulate cortex and medial
frontal/temporal gyrus.
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Table 1 | Comparison of brain structural and functional alteration in
diabetes and Alzheimer disease.
Diabetes Alzheimer disease
Structural
change
Gray matter
loss
Frontal, temporal
lobes, hippocampus
(3, 11, 12), anterior
cingulate cortex (11)
Temporal lobe,
hippocampus,
entorhinal, and parietal
lobes (13–15)
White matter
loss
Frontal and temporal
regions (11)
Temporal region (16)
Functional
change
Aberrant
functional
connectivity
Between posterior
cingulate cortex and
medial frontal
(20)/temporal (19)
gyrus
Between posterior
cingulate cortex and
hippocampus in medial
temporal lobe (17, 18)
Decreased
spontaneous
brain activity
Occipital lobe and
postcentral gyrus (21)
Posterior cingulate
cortex, medial
temporal lobe (23)
Task-induced
brain activity
Reduced activation of
dorsolateral prefrontal
cortex during
encoding and
deactivation of default
mode network during
recognition (22)
Reduced activation in
hippocampal formation
but increased
activation in medial
parietal and posterior
cingulate regions
during encoding (24)
CLINICAL SYMPTOMS IN DEMENTIA ASSOCIATED WITH
DIABETES
Diabetic patients show impaired cognitive function, increased
behavioral symptoms, and decreased activity of daily living
(Table 2). Diabetic patients show impairment of memory (25),
attention (26, 27), executive function (28, 29), information pro-
cessing (28, 29), planning (11), visuospatial construction (11), and
visual memory (11, 21). Diabetic patients are reported to have
impaired memory retrieval rather than encoding (25). Patients
with higher HbA1c have increased behavioral and psycholog-
ical symptoms (30) such as apathy, overeating, and excessive
daytime sleeping, and also have impaired activities of daily liv-
ing (30). Therefore, the knowledge about brain alterations and
clinical symptoms suggests that diabetes affects cognitive func-
tion through not only simply AD pathological feature-dependent
mechanisms but also independent mechanisms (Figure 1).
ALZHEIMER PATHOLOGICAL FEATURE-INDEPENDENT
MECHANISMS
VASCULAR MECHANISM
Cerebrovascular damage is related to cognitive function (42–
45) and brain atrophy (46). Diabetes is associated with vascular
reactivity impairment (47, 48), microangiopathy (49), and cere-
brovascular lesions (50), including subcortical infarcts (3). Indeed,
microvascular network alteration in the retina, which is believed
to be a predictor of vascular changes inside the brain, is asso-
ciated with increased risk of cognitive dysfunction (51) and AD
Table 2 | Comparison of cognitive and behavioral alterations in
diabetes and Alzheimer disease.
Diabetes Alzheimer
disease
Cognitive
function
Memory Decreased (25) Decreased (31, 32)
Attention Decreased (26, 27) Decreased (31, 32)
Executive
function
Decreased (28, 29) Decreased (32)
Information
processing
Decreased (28, 29) Decreased (33), but
less in initial phase
Planning Decreased (11) Decreased (34)
Visuospatial
construction
Decreased (11) Decreased (35, 36)
Visual memory Decreased (11, 21) Decreased (37)
Behavioral
psychological
symptom
Apathy Increased (30) Increased (38)
Overeating Increased (30) Increased (39), but
less in initial phase
Excessive
daytime
sleeping
Increased (30) Increased (40)
Activity of
daily living
– Decreased (30) Decreased (41)
(52) in diabetes. Vascular permeability is reported to be increased
in diabetic retinopathy (53), suggesting that diabetes disrupts
the blood–brain barrier (BBB) inside the brain. These data sug-
gest that diabetes compromises cerebrovascular function, increases
subcortical infarction, and might cause BBB dysfunction.
METABOLIC MECHANISM
Hyperglycemia and hypoglycemia – brain glucose metabolism
Hyperglycemia and hypoglycemia have impacts on cognitive func-
tion and activity of daily life. Interestingly, Holmes et al. demon-
strated that attention and fine motor skills were slowed at altered
glucose levels, assessed in diabetic patients during hypoglycemia
and hyperglycemia induced by an artificial insulin/glucose infu-
sion system (27). In the long term, the duration of diabetes is
associated with impaired cognition in patients with higher HbA1c
levels (54). Glucose metabolism declines with age in many brain
regions (55), and glucose hypometabolism and brain atrophy are
associated with concurrent cognitive dysfunction (56).
Hypoglycemia is associated with cognitive impairment in
elderly diabetic patients (57). Because the brain uses mainly glu-
cose as an energy source, hypoglycemia causes defects of neu-
ronal function, though lactate can also be used in such situations
(58, 59). In addition to dysfunction of individual cells, failure
of neuronal networking also contributes to cognitive impair-
ment in a hypoglycemic state (60). In the long term, repeated
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FIGURE 1 | Association of dementia with diabetes: Aβ/tau-dependent
and independent mechanisms. Diabetes modifies cognitive function
through Aβ/tau-dependent and independent mechanisms. Interaction
between these two mechanisms forms a vicious cycle.
episodes of severe hypoglycemia are reported to also be a risk for
the development of dementia (61). Hyperglycemia affects cogni-
tive function, and is associated with brain hypometabolism (62),
impaired deactivation of the default mode network (22), poorer
memory, and reduced hippocampal microstructures (63). Behav-
ioral and psychological symptoms, including apathy, overeating,
and excessive daytime sleeping, appear to be increased in patients
with HbA1c ≥7.0% (30). In an animal model, hyperglycemia
induced by a high-fat diet causes chronic energy imbalance with
resulting loss of neurons and reduces olfactory learning (64). These
studies suggest that hyperglycemia has an impact on cognition
and behavior through glucose-energy imbalance. Although the
memory in diabetes (MIND) sub-study of action to control car-
diovascular risk in diabetes (ACCORD) suggests that intensive
glycemic control has no effect on cognitive function (65), the inci-
dence of hypoglycemia should be considered in interpreting the
data (66).
Hyperinsulinemia – brain insulin signaling
Insulin signaling is believed to be decreased in the diabetic brain.
Insulin receptors are expressed in the cortex and hippocampus
(67–69), and peripheral insulin accesses the brain by crossing the
BBB (70). Insulin is also produced in the CNS. Indeed, single-cell
PCR reveals that insulin is strongly expressed in GABAergic neu-
rogliaform cells in the cerebral cortex (71). Similarly, insulin-like
growth factor-1 (IGF-1), IGF-2, and their receptors exist in the
CNS (72–75). When insulin binds to the insulin receptor, IRS-1
and -2 (insulin receptor substrate) undergo tyrosine phosphory-
lation and bind phosphatidylinositol 3-kinase (PI3K) (76), which
activates AKT and glycogen-synthase kinase-3β (GSK3β) (77–79).
Importantly, insulin receptor knockout mice show no obvious
alteration in the brain (80), suggesting compensation of IGF recep-
tor signaling for insulin signaling. Liu also reported that the levels
and activities of several components of the insulin–PI3K–AKT
signaling pathway were decreased in patients with diabetes (81).
Taken together, these findings indicate that insulin/IGF signaling
is impaired in the diabetic brain, and this signaling might have an
impact on aging-related brain dysfunction (82). Interestingly, aer-
obic exercise increases some proteins related to the insulin/IGF-1
pathway in the hippocampus and improves spatial memory in
diabetic rats (83).
Brain mitochondrial metabolism
Diabetes deregulates mitochondrial function in mouse (84) and
rat (85) neurons. Recent work reveals that hyperglycemia mediates
a phenotypic change in mitochondrial biology through alteration
of AMP-activated protein kinase (AMPK), a key cellular energy
sensor that regulates the activity of a number of metabolic enzymes
(86). It is known that an anti-diabetic drug, metformin, activates
AMPK kinase. These findings might explain the recent clinical
observation that use of metformin is associated with increased risk
of cognitive impairment in patients with diabetes (87), though this
is still controversial (88). Diabetes is also reported to impair neu-
rite outgrowth through JAK/STAT3 modulation of mitochondrial
bioenergetics in neurons (89). Thus, mitochondria might be a new
therapeutic target not only for diabetic neuropathy (90) but also
for dementia associated with diabetes.
ALZHEIMER PATHOLOGICAL FEATURE-DEPENDENT
MECHANISMS
Aβ-DEPENDENT MECHANISM
While AD consists of both familial and sporadic forms, familial
AD is caused by mutations in the amyloid precursor protein (91)
and presenilin (92). Both mutations cause overproduction of Aβ,
particularly its longer form, Aβ42, which is more prone to aggre-
gate in vitro (93) and deposits first in the brain (94) to form senile
plaques. Insulin resistance in mid-life is associated with the devel-
opment of senile plaques (8), though retrospective studies suggest
that the magnitude of senile plaques and another hallmark, neu-
rofibrillary tangles, is comparable between AD with and without
diabetes (95). Several groups report that a high-fat diet causes Aβ
accumulation in the brain of wild type rabbits (96) and APP Tg
mice (97, 98). Accumulation of autophagosomes to enhance amy-
loidogenic APP processing (99) or up-regulation of BACE1 (100)
have thus far been proposed as the mechanisms of the increase in
Aβ by diabetes. APP+-ob/ob mice, produced by crossing of dia-
betic and obese ob/ob mice, manifest no change in total brain Aβ
level, but increase Aβ deposition in the cerebral vasculature (101).
APP+-ob/ob mice show up-regulation of RAGE, the receptor for
AGE (102), in the vasculature. Because RAGE mediates amplifica-
tion of inflammatory responses (103), inflammatory cytokines are
upregulated around the cerebrovasculature in APP+-ob/ob (101).
Soluble Aβ itself is believed to reduce endothelial function in vitro
(27) and vascular reactivity in mice (104) and humans (105, 106).
Interestingly, crossing obese and diabeticdb/db mice with APP/PS1
knock-in mice leads to severe cerebrovascular pathological fea-
tures, including aneurysms and small strokes, though no further
Aβdeposition in the vasculature, indicating an interaction between
soluble Aβ and a diabetic vascular factor (107).
Glucose-energy metabolism is altered in AD (108) and vari-
ous AD models (109–111). Amyloid burden is accompanied by
glucometabolic increases in people at risk for AD (108). Brain
18FDG uptake is a sensitive biomarker for early detection of
abnormal metabolism in the 5XFAD mouse (109), indicating
that glucose metabolism is decreased in the AD model brain. A
glucose transporter, Glut-1, is reduced in the brain capillaries
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of 18-month-old 3xTg-AD mice (110), suggesting that glucose
uptake into the brain might be altered. Another AD model,
APP/PS1 mice, also shows alterations in energy-sensor AMPK
(111). AMPK could mediate the toxic effects of Aβ through tau
phosphorylation (112).
Insulin signaling is also altered by Aβ. In the AD brain, the lev-
els of insulin and IGF (113) and the responses to insulin and IGF
(114) are reduced. The levels and activities of the insulin signaling
pathway are also decreased in AD (81, 115) and diabetic brains
(81), as mentioned above. AD animal models show significant
reductions in insulin receptor (111), IRS-1 (116), and IRS-2 (111)
in the brain. Therefore, diabetes and Aβ could synergistically affect
insulin signaling (101, 117, 118). This impaired insulin signaling
could lead to an increase of tau phosphorylation.
Tau-DEPENDENT MECHANISM
Diabetes could promote tau phosphorylation, and then formation
of neurofibrillary tangles, which is one of the major pathological
features of AD. Normal tau promotes the assembly and stabiliza-
tion of microtubules, but abnormally hyperphosphorylated tau
sequesters normal tau and disrupts microtubules (119, 120). Sev-
eral neuropathological studies suggest that the magnitude of neu-
rofibrillary tangles in the brain at autopsy is not different between
AD with and without diabetes (95). However, animal studies show
that tau phosphorylation is increased in diabetes (121–125). Tau
phosphorylation is increased in the cortex and hippocampus in
db/db mice (121) and streptozotocin-induced diabetic mice (122–
124). Moreover, streptozotocin exacerbates neurofibrillary tangles
in a transgenic mouse model over-expressing the P301L mutant
human tau (125). Recently, Takalo et al. report that a high-fat diet
induces the expression of four repeat tau mRNA and protein in the
temporal cortex (126). Importantly, tau phosphorylation sites in
AD are shown to be increased in the diabetic human brain (127).
These data suggest that diabetes promotes tau phosphorylation,
splicing, and the formation of neurofibrillary tangles.
Impaired insulin signaling in the brain could cause tau phos-
phorylation (128) and insulin signaling is mainly mediated
through the PI3K–AKT–GSK3β pathway (77–79). Because GSK3β
phosphorylates tau, insulin inhibits tau phosphorylation through
negative regulation of GSK3β (129). Therefore, loss of insulin
(130), insulin receptor (80), or IRS-2 (131–133) increases tau
phosphorylation. While protein phosphorylation is also regulated
by kinases and phosphatases, tau is reported to be dephospho-
rylated by protein phosphatase 2A (PP2A) (134). As disruption
of IRS-2 downregulates PP2A (134), impaired insulin signaling
might cause tau phosphorylation by influencing not only kinases
but also phosphatases. Importantly, depletion of endogenous tau
mitigates behavioral impairment and synaptic deficits induced
in diabetic mice (135). Taken together, these findings indicate
that diabetes could promote tau phosphorylation via impaired
insulin signaling in the brain and then, contribute to cognitive
impairment.
CONCLUSION
Morphologically, diabetes is associated with neuronal loss in the
frontal and temporal lobes including the hippocampus, and aber-
rant functional connectivity of the posterior cingulate cortex and
medial frontal/temporal gyrus, and decreased spontaneous brain
activity in the occipital lobe and postcentral gyrus. As clinical
symptoms, diabetic patients show decreased executive function,
information processing, planning, visuospatial construction, and
visual memory. Therefore, in comparison with the character-
istics in AD brain structure and cognition, diabetes seems to
affect cognitive function through not only simply AD pathological
feature-dependent but also independent mechanisms. As Aβ/tau-
independent mechanisms, diabetes compromises cerebrovascular
function, increases subcortical infarction, and might alter BBB.
Diabetes also compromises glucose metabolism, insulin signaling,
and mitochondrial function. Diabetes also modifies metabolism
of Aβ and tau and causes Aβ/tau-dependent pathological changes.
Interestingly, in cognitively normal diabetic subjects, higher mean
HbA1c levels are associated with lower cognitive performance in
ApoEε4 carriers (136), indicating an interaction between Aβ/tau-
dependent and independent mechanisms. In conclusion, diabetes
modifies cognitive function through Aβ/tau-dependent and inde-
pendent mechanisms. Interaction between these two mechanisms
forms a vicious cycle.
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